

Review Article

Fructose Metabolism and Relation to Atherosclerosis, Type 2 Diabetes, and Obesity

Astrid Kolderup¹ and Birger Svihus²

¹Faculty of Public Health, Hedmark University College, P.O. Box 400, 2418 Elverum, Norway

²Norwegian University of Life Sciences, P.O. Box 5003, 1432 Aas, Norway

Correspondence should be addressed to Astrid Kolderup; astrid.kolderup@hihm.no

Received 17 April 2015; Revised 4 June 2015; Accepted 7 June 2015

Academic Editor: Michael B. Zemel

Copyright © 2015 A. Kolderup and B. Svihus. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

A high intake of sugars has been linked to diet-induced health problems. The fructose content in sugars consumed may also affect health, although the extent to which fructose has a particularly significant negative impact on health remains controversial. The aim of this narrative review is to describe the body's fructose management and to discuss the role of fructose as a risk factor for atherosclerosis, type 2 diabetes, and obesity. Despite some positive effects of fructose, such as high relative sweetness, high thermogenic effect, and low glycaemic index, a high intake of fructose, particularly when combined with glucose, can, to a larger extent than a similar glucose intake, lead to metabolic changes in the liver. Increased *de novo* lipogenesis (DNL), and thus altered blood lipid profile, seems to be the most prominent change. More studies with realistic consumption levels of fructose are needed, but current literature does not indicate that a normal consumption of fructose (approximately 50–60 g/day) increases the risk of atherosclerosis, type 2 diabetes, or obesity more than consumption of other sugars. However, a high intake of fructose, particularly if combined with a high energy intake in the form of glucose/starch, may have negative health effects via DNL.

1. Introduction

Sugars are important sources of energy in our diet, and a high intake of sugars has increasingly been identified as a considerable cause of major diet-induced health problems, namely, atherosclerosis, type 2 diabetes, and obesity [1–4]. An increased intake of sugar sweetened beverages in particular has been associated with these health problems in many epidemiological studies [5–7]. The main constituents of sugars are fructose and glucose, which can be present either alone or in combination, although most commonly fructose is mixed 50:50 with glucose. The ratio of glucose:fructose in the diet has been argued to be important for some of the effects of sugars [8, 9]. Thus, it is important to study the effects of fructose and glucose together, but also it is important to study the effects of fructose alone. Fructose has been claimed to be of benefit because it may aid glycemic control [10, 11], but also it has been claimed to be more harmful than other sugars,

especially with regard to the development of atherosclerosis, type 2 diabetes, and obesity [8].

Fructose is found in a variety of foods. In table sugar, it is bound to glucose to form the disaccharide sucrose, whereas in honey it occurs in monosaccharide form. In fruit, berries, and vegetables, fructose occurs in both monosaccharide and disaccharide forms. Measured as intake from caloric sweeteners in USA, fructose intake was rather stable throughout the fifties and sixties but increased from the seventies until the end of the nineties, after which intake has declined [12]. The average American fructose intake was estimated to be 49 g per day in 2004 [13]. In Norway, the average daily intake of fructose can be estimated to be approximately 56 g/day, based on data from the Norwegian Directorate of Health's survey of consumption patterns [14] and composition data [15]. Globally, the main source of fructose is sucrose, which constitutes >90% of the energizing sweeteners used in the world [16]. In some countries, such as USA and Japan,

high-fructose corn syrup (HFCS) is also an important source of fructose. HFCS is a mixture of fructose and glucose in different concentrations. It can contain up to 90% fructose [17], but the dominating concentration of fructose is 42% or 55% in commercial products [9]. In USA, consumption of HFCS increased sharply from 1970 until 1999, but it has declined since then [12, 18].

This review paper aims to describe how fructose, compared with other sugars, is managed by the body, thus clarifying the impact of fructose on atherosclerosis, type 2 diabetes, and obesity.

2. Materials and Methods

The review is based on scientific peer-reviewed papers obtained using a nonsystematic search of the databases PubMed and Web of Science. The first step in the selection of literature was to identify the relevant keywords to search for in these databases. Various combinations of the following keywords were used: “fructose,” “glucose,” “sucrose,” and “sugar” combined with “metabolism,” “insulin resistance,” “overweight,” “obesity,” “relative sweetness,” “absorption capacity,” “glycemic index,” “de novo lipogenesis,” “thermogenesis,” “type 2 diabetes,” and “appetite regulation.”

The next step in the selection process consisted of inclusion or exclusion of papers based on the relevance to the study's aim. Through this initial selection process, both original and review papers were included. The reference lists of the papers were thoroughly studied to discover any possibly relevant papers that were not included. As far as possible, only original papers and reviews based on controlled trials and mechanistic studies were included. Unless otherwise specified, the results presented and discussed in this paper are statistically significant, and the experiments were conducted with a control group. Although animals may metabolize fructose differently from humans, animal studies have been included when found relevant, for example, due to lack of human studies. One possible limitation in this study lies in the nonsystematic nature of the search strategy, resulting in the possibility that relevant papers were not considered.

3. The Body's Fructose Management

3.1. Absorption. Although there is some uncertainty about the mechanisms of fructose absorption, most of fructose seems to be absorbed by facilitated transport in the jejunum by the fructose transporter GLUT5 [18–20]. The body has limited capacity to absorb pure fructose, and intake of fructose can therefore lead to malabsorption [20–24]. Malabsorption of fructose results in bacterial fermentation, which leads to formation of short-chain fatty acids (acetate, propionate, and butyrate) and gases (hydrogen, methane, and carbon dioxide) [25, 26]. These processes can affect the motility of the intestine and cause various symptoms such as abdominal pain, bloating, and altered stool [27]. A large individual variation in absorption capacity for fructose has been observed. When fructose is consumed as a single oral dose, the maximum absorption capacity has been shown to vary between 5 and 50 g [28]. Several factors seem to affect

this capacity, such as age and health [27, 29, 30], but of the dietary factors the presence of glucose is the most important [20, 23]. A significant increase in fructose absorption has been shown when fructose is coingested with equal amounts of glucose [21, 31]. There is still uncertainty about how glucose increases absorption capacity for fructose, but it may amongst others be due to an effect of glucose on the presence of fructose transporters [20]. Fructose does not appear in any fruit or vegetable without glucose [15]. Evolutionarily, this may explain why humans do not have the ability to absorb large amounts of pure fructose.

3.2. Metabolism. After absorption, fructose is transported by the portal vein to the liver, where it is effectively absorbed by liver cells [32], resulting in only small amounts entering the systemic circulation. The concentration of fructose in the blood is therefore only about 0.01 mmol/L, unlike that of glucose which is approximately 5.5 mmol/L [33]. Metabolism of fructose thus occurs primarily in the liver, but fructose may also be metabolized by enterocytes. In a study of pigs, it was shown that intestinal lactate production from fructose could account for 12% of absorbed fructose [34], but the functional significance of intestinal metabolism of fructose in humans remains unknown [18]. Bjorkman and Felig [35] also showed that infused fructose (48.6 g fructose in liquid form infused intravenously) was metabolized in the kidneys in humans who had fasted for 60 hours. Despite the artificially high blood fructose level, that study still shows that the kidneys have a relatively large capacity to metabolize fructose. It has been shown that GLUT5 is expressed in the membrane of fat, kidney, muscle, and brain cells [32, 36], but, due to very low levels of fructose in the blood, negligible amounts of fructose are probably metabolized in these tissues [9, 18].

As discussed above, the liver will metabolize a large majority of the ingested fructose, compared to only about 15–30% of ingested glucose [37, 38]. Most of the reactions in liver fructolysis are the same as those occurring in glycolysis, but fructose enters at a later stage in the glycolytic reaction chain than glucose [39]. Thus, fructose avoids the main control step in glycolysis, the phosphofructokinase step, which is tightly regulated by the energy status of the cell. The first step in fructolysis is the phosphorylation of fructose by fructokinase to fructose 1-phosphate. Unlike the phosphofructokinase in glycolysis, this enzyme is not inhibited by ATP [40]. The enzyme is considered virtually unregulated and, even when the liver's energy status (ATP) is high, the fructokinase will metabolize fructose to fructose 1-phosphate. Furthermore, fructose 1-phosphate is cleaved to dihydroxyacetone phosphate and glyceraldehyde by the enzyme aldolase B. Glyceraldehyde may be phosphorylated by triose kinase, with ATP as the phosphate donor, to form the glycolytic intermediate glyceraldehyde 3-phosphate [41]. After these steps, the carbon atoms from fructose follow the glycolytic steps.

Bypassing the phosphofructokinase step makes the flow of fructose carbon atoms through the biochemical pathways less controlled than for glucose. In this way, the liver will metabolize fructose in an unlimited way, as opposed to the case of glucose. This will influence the type and amount of

metabolic products produced by the liver and is the main reason why fructose and glucose have different metabolic effects.

In the liver, fructose can enter metabolic pathways: it can be oxidized, converted to glucose (and glycogen), or converted to lactic acid, or enter *de novo* lipogenesis (DNL). After an overnight fast, approximately 50% of the fructose eaten as an oral dose of approximately 30–70 g is converted to glucose via gluconeogenesis [42]. Others have shown that after a similar fructose intake about 45% is oxidized; however, this includes both direct fructose oxidation and oxidation of glucose and lactic acid formed from fructose [43]. Another metabolic fate of fructose is to form lactic acid, but this seems to occur only at high fructose intakes [44–48]. The ingestion of 72 g fructose is the lowest amount that has been experimentally demonstrated to result in lactic acid formation [49]. Intake of fructose may also lead to formation of fatty acids via DNL. The diet composition may influence the distribution of fructose. Theytaz et al. [50] showed that coingestion of glucose with fructose decreased oxidation and gluconeogenesis from fructose carbon atoms. Intake of fructose together with glucose thus seems to affect the metabolic fate of fructose. To some degree, this effect may be due to higher insulin secretion after intake of glucose compared to fructose [51]. Insulin will, amongst others, decrease glucose production from fructose [52], and insulin will also stimulate DNL [53]. The extent to which fructose enters DNL is central to the health effects of fructose.

3.3. *De Novo Lipogenesis (DNL)*. DNL is the metabolic pathway that transforms surplus nonfat energy into fat by synthesis of fatty acids from acetyl-CoA [54]. The liver is the primary site of DNL, but DNL can also occur in lactating mammary glands and adipose tissue. Key lipogenic enzymes are present in adipose tissue, but to what degree adipose tissue contributes to the total DNL seems to be unclear. Although some data indicate that DNL in adipose tissue is of little importance [55–57], it has also been shown that it may play a more significant role [58], especially after ingestion of large amounts of carbohydrates [59, 60]. Some controversy exists regarding the capacity of the liver to carry out *de novo* lipogenesis in humans [60, 61], although a high capacity has been demonstrated in several experiments [62, 63].

As a result of the metabolic difference between glucose and fructose, a higher percentage of fructose compared to glucose can be converted to fat in the liver via DNL [63]. This has been shown in a number of animal and human studies, in which these sugars have been consumed in equal quantities under similar experimental conditions [63–66]. The greater potential of fructose to stimulate DNL is the main reason why fructose has been portrayed as particularly harmful. As described earlier, the liver absorbs most of the ingested fructose, and fructose metabolism bypasses the main control step in glycolysis, which means that a greater proportion of fructose, compared with glucose, is available for DNL. A normal diet, however, provides 3 to 5 times more glucose than fructose [12, 67], and this may influence the practical relevance of this metabolic difference. If, for example, glucose intake is very high, the liver may need to

handle larger amounts of glucose than fructose. At two points in liver fructolysis, intermediates can enter lipid synthesis [9]. Fructose is converted to dihydroxyacetone phosphate, an intermediate in equilibrium with glycerol 3-phosphate, which forms the basis for the glycerol in triglycerides and phospholipids. Meanwhile, a large proportion of fructose carbons are metabolized directly to pyruvic acid and then acetyl-CoA. On metabolism of a large amount of fructose to acetyl-CoA, the amount of acetyl-CoA may exceed the citric acid cycle capacity of mitochondria. High levels of fructose may thus act as a nonregulated source of hepatic acetyl-CoA, which is a substrate that can enter DNL [9]. In addition, a high intake of fructose seems to stimulate gene expression and activity of lipogenic enzymes in the liver [40, 41, 66, 68]. Recently, fructose has also been shown to give a higher increase in fibroblast growth factor 21 (FGF21) than glucose. FGF21 is a hormone involved in glucose and lipid homeostasis [69], and high levels of FGF21 seem to be associated with metabolic disease [70].

It is clear that a high intake of fructose will cause a significant increase in DNL activity [71]. However, there is a paucity of knowledge about the effect of a normal fructose intake on this activity [72]. No research seems to have been conducted to assess the minimum amount or individual range of fructose that must be eaten to obtain a significant increase in DNL, which among others may be due to difficulties in quantifying DNL. In fact, measurement of hepatic DNL must be considered semiquantitative [54, 73]. Chong et al. [73] found that ¹³C-labelled fructose contributed only 0.4% of the triglycerides in very-low-density lipoproteins (VLDLs) in men. This was measured 6 hours after eating a meal of 0.5 g fat/kg body weight and 0.75 g fructose/kg body weight after an overnight fast. The small increase in triglyceride levels in the blood after a fructose intake may be a result of delayed triglyceride secretion. Incorporation of carbon from ¹³C-labelled fructose in VLDLs will not always reflect DNL, because some of the newly synthesized fatty acids will have delayed secretion [74, 75]. The level of DNL activity after fructose intake seems to vary significantly among individuals [76–78], and it also seems to vary during the day [79, 80].

Excessive intake of fructose, and hence increased DNL, may increase the risk of disease, because it may potentially cause both increased cholesterol levels in the blood and accumulation of fat in the liver [81]. In several animal studies, fat accumulation in the liver has been demonstrated after a high intake of fructose [82, 83], although most human studies have failed to demonstrate such an effect [84–86]. In fact, Chiu et al. [87] concluded, based on a systematic review with meta-analysis of controlled feeding trials, that fructose does not increase lipid content in liver when isocalorically exchanged for other carbohydrates. However, they pointed out that fructose ingested in large doses can raise liver lipid content, an effect that may be due to excess energy rather than fructose per se. Bravo et al. [88] conducted a study where participants consumed sucrose or HFCS for ten weeks at different levels of intake. In the study, fructose consumed as a part of a normal diet did not promote increased liver lipid

content even at high intakes (90th percentile consumption level). In a study referred to by Rippe and Angelopoulos [89], no increase in liver fat was observed after consumption of HFCS or sucrose at levels up to 30% of energy for ten weeks. However, Maersk et al. [90] found that intake of 1L sucrose-sweetened soft drink per day for six months increased liver lipids in overweight participants compared with intake of same amount of milk, diet cola, and water. This may illustrate that the combination of fructose and glucose, as in sucrose, can lead to increased level of liver lipids. However, it is not possible to conclude that this is an effect of fructose, since there was no glucose control group in this study. Johnston et al. [91] found no difference in liver triglyceride level between overweight participants that ate a hypercaloric high-fructose or high-glucose diet. The authors concluded that this result indicates that the hypercaloric state rather than macronutrient composition is important for the accumulation of liver lipids. Carbohydrate-induced accumulation of fat in the liver can lead to nonalcoholic fatty liver disease (NAFLD) [92]. However, it is still unclear if fructose via increased DNL is particularly conducive to NAFLD [93]. The effect of fructose on lipid accumulation is thus unclear, but the effect of fructose on the blood lipid profile seems to be better documented.

4. Atherosclerosis

It appears that high fructose intake can create an unfavorable lipid profile in blood via DNL [94]. The main product of DNL is palmitic acid [95], a fatty acid specifically shown to increase the risk of atherosclerosis [96]. Fatty acids formed by DNL will mainly be packed in VLDLs delivered into the bloodstream. This may, in turn, increase the level of low-density lipoproteins (LDLs) in the blood. In several studies, fructose has to a greater extent than glucose increased blood levels of triglycerides [51, 65, 97, 98] and LDLs [65, 99–103]. Aeberli et al. [104] showed that fructose increased the small dense LDLs, the type of LDLs that may in particular be linked to cardiovascular risk [105]. The level of high-density lipoproteins (HDLs) in blood does not seem to be affected by fructose [100, 101]. In most studies, an intake of fructose >100 g/day has been necessary to observe the adverse effects on lipid profiles [51, 65, 85, 98, 100, 106–108]. However, in a recent study by Aeberli et al. [109], a daily intake of about 77 g fructose and 34 g glucose for 3 weeks resulted in increased levels of total cholesterol and LDLs in the blood of healthy young men, compared with a daily intake of approximately 109 g glucose and 28 g fructose over the same time period. The fact that both groups also ingested an unknown amount of starch and the fact that food intake was not controlled reduce the solidity of these results. Maersk et al. [90] found that intake of 50 g fructose per day together with 50 g glucose could have a negative effect on blood triglyceride level. The lack of a control group ingesting glucose makes it difficult to conclude that this is an effect of fructose. Conversely, Lowndes et al. [110] found no negative effect on lipid profile in overweight or obese individuals consuming HFCS or sucrose incorporated in a eucaloric diet for ten weeks at levels corresponding to the 25th and 50th percentiles of adult

fructose consumption. Using the current knowledge, it does not appear that the consumption of moderate amounts of fructose (<50 g/day) alone will result in an unfavorable blood lipid profile [86, 111].

Due to the insignificant levels of fructose in peripheral blood, as described above, only glucose has the potential to be a substrate for DNL in adipose tissue. Although DNL in adipose tissue seems to be small as earlier discussed, glucose will, because of its presence in blood and by raising blood insulin level, probably to a higher extent than fructose, stimulate DNL in adipose tissue. Intake of glucose, in amounts that exceed the total capacity for glycogen storage and glucose oxidation, may thus increase DNL in adipose tissue more than the same amount of fructose. While fat formed in the liver has to be transported as lipoproteins in blood, this is avoided if the fat is formed directly in adipose tissue. Considering known negative health effects of lipoprotein residues, DNL occurring in adipose tissue may be preferable compared with DNL in the liver. This may illustrate a metabolic difference between glucose and fructose when consuming large amounts of sugars.

Another possible difference between fructose and glucose on risk factors for atherosclerosis is the effect of these sugars on blood uric acid level. Increased uric acid level has been associated with atherosclerosis in epidemiological studies, but the causality is uncertain [112–114]. Fructose appears to increase uric acid levels in the blood to a higher extent than glucose, especially at high intakes and when consumed as excess energy [86, 115, 116]. Intake of 0.5 g fructose/kg body weight is the lowest quantity shown to result in uric acid formation [117]. An increased blood level of uric acid can theoretically lead to elevated blood pressure because uric acid inhibits an enzyme in the endothelial cells of the arteries called endothelial nitric oxide synthase (eNOS). Activated eNOS leads to increased production of nitric oxide (NO), an important vasodilator. Thus, inhibition of eNOS may lead to vasoconstriction. Although only 0.5 g fructose/kg body weight has been shown to give uric acid formation and increased uric acid level theoretically could increase blood pressure, results from studies of the effect of fructose on blood pressure are very inconsistent [65, 72, 118, 119]. An average intake of fructose does not seem to lead to increased blood pressure [111, 120, 121]. The lack of causal link between uric acid level and atherosclerosis makes it difficult to draw conclusions on this effect of fructose.

5. Type 2 Diabetes

A high intake of sugar-sweetened beverages, with fructose as one of the major types of monosaccharides, has been associated with development of type 2 diabetes [5, 122]. Although this association does not prove causation, it is important to study the role of fructose in the development of type 2 diabetes. Central to the understanding of type 2 diabetes is the effect of nutrients on blood glucose homeostasis. Fructose must be converted to glucose in the liver to cause an increase in blood glucose level. As the conversion takes time and only a portion of the fructose will form glucose, fructose increases blood glucose less than similar levels of glucose [51]. Thus,

the glycemic index for fructose is only 23 [10]. This, together with lack of stimulation of the pancreatic β cells [123], gives lower insulin secretion after intake of fructose compared with glucose [51, 124, 125]. These effects are positive because they contribute to blood glucose homeostasis. Additionally, moderate amounts of fructose have been shown to have positive effects on glycemic control [86, 126, 127]. However, it is claimed that fructose may also contribute negatively to blood glucose homeostasis by causing insulin resistance in the liver [9]. There is evidence that a high intake of fructose can cause insulin resistance in animals [128, 129], but several human studies have failed to demonstrate such an association [103, 130–132]. The operational definition of insulin resistance or sensitivity seems unclear, and many different methods have been used to measure it [133]. Thus, it is difficult to compare studies of insulin resistance. In human studies, in which fructose has been reported to cause insulin resistance, the daily intake of fructose has been as high as 110 g [109], approximately 250 g [134], 80 g [135], and 138 g [65]. This may indicate that the fructose intake must be high to potentially cause insulin resistance [86]. In the studies by Aeberli et al. [109], Stanhope et al. [65], and Beck-Nielsen et al. [134], total food intake was not controlled. Thus, the observed effect of fructose may also have been caused by differences in food intake between the control and experimental groups. In all the studies, in which insulin resistance has been shown, fructose was eaten together with glucose or starch, so the observations could also be the result of a combination of fructose and glucose. A number of hypotheses on how fructose can cause insulin resistance in the liver have been proposed. Lipid accumulation in the liver [136–138], meta-inflammation [83], and oxidative stress [139] are, either via inhibitory phosphorylation of the insulin receptor or the signaling molecules involved in insulin signaling, possible mechanisms for fructose-induced insulin resistance [9]. However, there are too few studies in humans and these are too divergent to be able to conclude firmly that there is a link between the consumption of fructose and insulin resistance. More long-term studies in which the daily intake of fructose is moderate are needed.

6. Obesity

It is debatable whether fructose is less satiating than other sugars and thus can contribute to obesity through a high food intake. In a study by Page et al. [92], magnetic resonance (MR) images were taken of human brains after giving 75 g of a fructose or glucose drink. Glucose, but not fructose, reduced activity (regional cerebral blood flow) in the hypothalamus in the areas involved in energy regulation and reward systems; this is probably an indicator of satiety and may indicate that fructose is less satiating than glucose. Fructose will also to a lesser extent than glucose increase blood levels of insulin [51], leptin [51, 140], gastric inhibitory polypeptide [141], and glucagon-like peptide-1 [92], while at the same time it will attenuate levels of ghrelin less [51]. Although these hormonal effects may indicate that fructose is less satiating than glucose, this has not been confirmed in studies of the ability of fructose to satiate. In such studies, it has been shown that fructose

has a greater appetite-reducing effect than glucose, when intake occurs before a meal [142, 143], or that there is no difference in the effects on appetite between fructose and glucose [144, 145]. Therefore, the effect of fructose on appetite remains unclear.

Although it is conceivable that fructose, via lack of stimulation of satiety signals, could contribute to obesity, fructose has several properties that act against obesity. As previously mentioned, the small intestine has a limited capacity to absorb fructose. This can lead to malabsorption at least if large amounts are consumed and consumption occurs without glucose-providing nutrients. Malabsorption of fructose will make less fructose enter the bloodstream and thus less energy will be available to the cells. In this way the malabsorption will act against obesity. It has also been shown in numerous studies that fructose has a greater thermogenic effect than glucose [46, 146–148]. This means that the body uses more energy after eating fructose rather than glucose, so less energy will be available to be stored as fat. The relative sweetness of fructose is also greater than for glucose and sucrose [149, 150]. Although this will decrease with increasing temperature [151, 152], the high relative sweetness allows smaller amounts of fructose than glucose and sucrose to be used to achieve a particular sweetness in most applications. On the basis of these properties, it does not appear that fructose is more fattening than other sugars. This also agrees with experimental studies of the relationship between fructose intake and obesity in animals [153, 154] and humans [65, 86, 106, 155].

7. Substrate Oxidation

It has been proposed that fructose can inhibit lipid oxidation [146]. For liver lipid oxidation this is logical, because the liver acquires energy from fructose and thus does not need to oxidize fat. Fructose can also increase DNL. It would not be expedient to form and break down fat simultaneously in the liver, and increased levels of malonyl-CoA (due to active DNL) will inhibit β -oxidation [41, 156]. It would also be logical for fructose to increase total body lipid oxidation more than glucose due to fructose's smaller contribution as an extrahepatic energy source. In some studies, however, fructose has been shown to increase the respiration quotient (RQ), the ratio of CO_2 exhaled to O_2 consumed, [157] more than glucose. This indicates that fructose to a higher degree than glucose reduces total body lipid oxidation and increases total body carbohydrate oxidation. Blaak and Saris [158] conducted a study in which participants ate 75 g fructose, starch, or glucose after a 12-hour fast in a crossover study. Fructose resulted in a significantly larger increase in the RQ, measured 6 hours after ingestion, than both glucose and starch. Tappy et al. [146] also showed a greater increase in RQ 4 hours after ingestion of 75 g fructose, compared with similar healthy participants eating 75 g glucose. Schwarz et al. [46] conducted a similar study (75 g fructose/glucose) with the same result. These results may be explained by the fact that fructose, more than glucose, enters DNL under specific conditions. Due to the fact that RQ varies for different substrates (e.g., 1 for carbohydrates and 0.7 for fats), RQ is

used to determine the source of substrate oxidation [159]. However, during active DNL, CO_2 is produced without using O_2 . Simultaneous occurrence of DNL and carbohydrate oxidation can lead to RQ values greater than 1 [159]. An increased RQ caused by DNL can, therefore, be misinterpreted as reduced lipid oxidation and increased carbohydrate oxidation. Such a misinterpretation may have occurred in the studies described above. Thus the effect of fructose on total body substrate oxidation remains unclear.

8. Discussion

The distribution of fructose into metabolic pathways, especially DNL, is of key importance to the health effects of fructose. The distribution varies with the amount of fructose consumed, the duration of fructose exposure, the composition of diet/meal, and whether the measurement took place postprandially, after absorption, or under fasting conditions. Individual physiological, enzymatic, and endocrine factors are also important. Diet composition and the amount of fructose eaten and absorbed will be the focus of this discussion.

Malabsorption of fructose will affect the amount of fructose absorbed and can thus be an important confounding factor in studies in which factors that affect absorption capacity have not been taken into account [39]. Truswell et al. [21] showed that intake of 50 g fructose led to malabsorption in over 50% of the study participants. The results of studies in which fructose is malabsorbed can thus be inaccurate due to individual differences in the absorption capacity of fructose. As the small intestine has a large absorption capacity for glucose and a limited one for fructose, it is problematic to compare fructose with glucose as the sole carbohydrate source. In future studies, this should be controlled for, for example, by using the hydrogen breath test to assess fructose malabsorption.

The composition of diet and especially the amount of glucose/starch may have influence on the health effects of fructose. As fructose is present with glucose in most food products, it is more practical and relevant to look at the effects of fructose and glucose together than the effects of fructose alone. A larger increase in DNL after eating fructose and glucose together (50 : 50 glucose : fructose) rather than the same amount as pure glucose has been shown [63]. Eating glucose with fructose is likely to affect fructose's health effects by stimulating the flow of fructose to DNL [50]. This effect could be due to both increased absorption capacity for fructose when coingested with glucose and therefore greater availability of fructose carbon atoms going towards DNL and increased blood insulin levels when glucose is present in the diet. Insulin stimulates DNL directly and indirectly by inhibiting other important metabolic pathways for fructose, such as gluconeogenesis. It is also plausible that glucose will compete with fructose as an energy source for enterocytes and hepatic cells, thus making more fructose available for DNL. Coingestion of glucose with fructose has been shown to decrease oxidation and gluconeogenesis from fructose carbon atoms [50]. Thus, it appears that the combination of fructose and glucose is particularly unfortunate, although fructose is not a prerequisite for DNL. It is unclear how much

glucose/starch must be included with fructose for this effect to be significant.

The amount of fructose consumed seems to be of great importance to the effects of fructose on health. The negative health effects of fructose have mainly been demonstrated at high intakes, and several studies have found an average intake of fructose to cause no health problems [12, 110, 111, 160]. Although the average daily intake of fructose is 50–60 g/day, some of the population will consume larger amounts [161, 162], so the negative health effects of fructose may be relevant at least for a proportion of the population. Many of the current studies are poorly suited to determine health risks of fructose because (a) the fructose intakes are unrealistically high, (b) fructose is given in isolation and not mixed with other carbohydrates as in practice, and/or (c) the studies are conducted on animals. Differences between human and animal physiology limit their applicability to humans. There is a need for more human studies under conditions more similar to the way fructose is normally consumed. Such studies, particularly related to DNL, will be necessary to understand the effects of a normal fructose intake. The effects of fructose on triglyceride and cholesterol levels in the blood, fat accumulation in liver, and insulin signaling all seem to be linked to the extent to which fructose enters DNL. Surprisingly, there have been no satisfactory studies to assess the proportion of fructose that enters DNL at different levels of intake. Such studies should be carried out and should include intake of both pure fructose and fructose together with glucose.

It is also important to note that, despite the metabolic difference between glucose and fructose, glucose consumption far exceeds fructose consumption in the human diet [12]. This quantitative aspect must be considered when comparing the health effects of glucose and fructose.

9. Conclusion

Although there is a paucity of published literature regarding physiological effects of fructose in humans, current literature does not indicate that a normal consumption of fructose (approximately 50–60 g/day) increases the risk of atherosclerosis, type 2 diabetes, or obesity more than consumption of other sugars. However, a high intake of fructose, particularly if combined with a high energy intake in the form of glucose/starch, may have negative health effects via DNL. More studies are clearly needed, particularly studies under more realistic consumption levels of fructose.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

References

- [1] A. M. Cohen, A. Teitelbaum, M. Balogh, and J. J. Groen, "Effect of interchanging bread and sucrose as main source of carbohydrate in a low fat diet on the glucose tolerance curve

- of healthy volunteer subjects," *The American Journal of Clinical Nutrition*, vol. 19, no. 1, pp. 59–62, 1966.
- [2] L. H. Storlien, E. W. Kraegen, A. B. Jenkins, and D. J. Chisholm, "Effects of sucrose vs starch diets on *in vivo* insulin action, thermogenesis, and obesity in rats," *The American Journal of Clinical Nutrition*, vol. 47, no. 3, pp. 420–427, 1988.
- [3] A. Giaccari, G. Sorice, and G. Muscogiuri, "Glucose toxicity: the leading actor in the pathogenesis and clinical history of type 2 diabetes—mechanisms and potentials for treatment," *Nutrition, Metabolism and Cardiovascular Diseases*, vol. 19, no. 5, pp. 365–377, 2009.
- [4] M. R. Laughlin, "Normal roles for dietary fructose in carbohydrate metabolism," *Nutrients*, vol. 6, no. 8, pp. 3117–3129, 2014.
- [5] V. S. Malik, B. M. Popkin, G. A. Bray, J.-P. Després, W. C. Willett, and F. B. Hu, "Sugar-sweetened beverages and risk of metabolic syndrome and type 2 diabetes: a meta-analysis," *Diabetes Care*, vol. 33, no. 11, pp. 2477–2483, 2010.
- [6] R. Dhingra, L. Sullivan, P. F. Jacques et al., "Soft drink consumption and risk of developing cardiometabolic risk factors and the metabolic syndrome in middle-aged adults in the community," *Circulation*, vol. 116, no. 5, pp. 480–488, 2007.
- [7] A. T. Høstmark, "The Oslo Health Study: soft drink intake is associated with the metabolic syndrome," *Applied Physiology, Nutrition and Metabolism*, vol. 35, no. 5, pp. 635–642, 2010.
- [8] R. H. Lustig, "Fructose: metabolic, hedonic, and societal parallels with ethanol," *Journal of the American Dietetic Association*, vol. 110, no. 9, pp. 1307–1321, 2010.
- [9] P. J. Havel, "Dietary fructose: implications for dysregulation of energy homeostasis and lipid/carbohydrate metabolism," *Nutrition Reviews*, vol. 63, no. 5, pp. 133–137, 2005.
- [10] M. S. Segal, E. Gollub, and R. J. Johnson, "Is the fructose index more relevant with regards to cardiovascular disease than the glycemic index?" *European Journal of Nutrition*, vol. 46, no. 7, pp. 406–417, 2007.
- [11] L. G. Sánchez-Lozada, M. Le, M. Segal, and R. J. Johnson, "How safe is fructose for persons with or without diabetes?" *The American Journal of Clinical Nutrition*, vol. 88, no. 5, pp. 1189–1190, 2008.
- [12] J. S. White, "Challenging the fructose hypothesis: new perspectives on fructose consumption and metabolism," *Advances in Nutrition*, vol. 4, no. 2, pp. 246–256, 2013.
- [13] B. P. Marriott, N. Cole, and E. Lee, "National estimates of dietary fructose intake increased from 1977 to 2004 in the United States," *The Journal of Nutrition*, vol. 139, no. 6, pp. S1228–S1235, 2009.
- [14] Helsedirektoratet, "Utviklingen i norsk kosthold. Matforsyningsstatistikk," 2013, (Norwegian), <https://helsedirektoratet.no/Lists/Publikasjoner/Attachments/370/Utviklingen-i-norsk-kosthold-2013-matforsyningsstatistikk-IS-2116.pdf>.
- [15] United States Department of Agriculture, *National Nutrient Database for Standard Reference*, United States Department of Agriculture, 2012, <http://ndb.nal.usda.gov/ndb/search/list?fg=&man=&facet=&count=&max=&sort=&qlookup=&offset=&format=Full&new=>.
- [16] J. S. White, "Straight talk about high-fructose corn syrup: what it is and what it ain't," *The American Journal of Clinical Nutrition*, vol. 88, no. 6, pp. 1716S–1721S, 2008.
- [17] L. Ferder, M. D. Ferder, and F. Inserra, "The role of high-fructose corn syrup in metabolic syndrome and hypertension," *Current Hypertension Reports*, vol. 12, no. 2, pp. 105–112, 2010.
- [18] L. Tappy and K.-A. Le, "Metabolic effects of fructose and the worldwide increase in obesity," *Physiological Reviews*, vol. 90, no. 1, pp. 23–46, 2010.
- [19] M. Madero, S. E. Perez-Pozo, D. Jalal, R. J. Johnson, and L. G. Sánchez-Lozada, "Dietary fructose and hypertension," *Current Hypertension Reports*, vol. 13, no. 1, pp. 29–35, 2011.
- [20] H. F. Jones, R. N. Butler, and D. A. Brooks, "Intestinal fructose transport and malabsorption in humans," *The American Journal of Physiology—Gastrointestinal and Liver Physiology*, vol. 300, no. 2, pp. G202–G206, 2011.
- [21] A. S. Truswell, J. M. Seach, and A. W. Thorburn, "Incomplete absorption of pure fructose in healthy subjects and the facilitating effect of glucose," *The American Journal of Clinical Nutrition*, vol. 48, no. 6, pp. 1424–1430, 1988.
- [22] J. E. Riby, T. Fujisawa, and N. Kretschmer, "Fructose absorption," *American Journal of Clinical Nutrition*, vol. 58, no. 5, pp. S748–S753, 1993.
- [23] C. P. Corpe, C. F. Burant, and J. H. Hoekstra, "Intestinal fructose absorption: clinical and molecular aspects," *Journal of Pediatric Gastroenterology and Nutrition*, vol. 28, no. 4, pp. 364–374, 1999.
- [24] P. L. Beyer, E. M. Caviar, and R. W. McCallum, "Fructose intake at current levels in the United States may cause gastrointestinal distress in normal adults," *Journal of the American Dietetic Association*, vol. 105, no. 10, pp. 1559–1566, 2005.
- [25] M. Pimentel, H. C. Lin, P. Enayati et al., "Methane, a gas produced by enteric bacteria, slows intestinal transit and augments small intestinal contractile activity," *American Journal of Physiology—Gastrointestinal and Liver Physiology*, vol. 290, no. 6, pp. G1089–G1095, 2006.
- [26] J. M. W. Wong, R. de Souza, C. W. C. Kendall, A. Emam, and D. J. A. Jenkins, "Colonic health: fermentation and short chain fatty acids," *Journal of Clinical Gastroenterology*, vol. 40, no. 3, pp. 235–243, 2006.
- [27] P. R. Gibson, E. Newnham, J. S. Barrett, S. J. Shepherd, and J. G. Muir, "Review article: fructose malabsorption and the bigger picture," *Alimentary Pharmacology & Therapeutics*, vol. 25, no. 4, pp. 349–363, 2007.
- [28] J. L. Madsen, J. Linnet, and J. J. Rumessen, "Effect of non-absorbed amounts of a fructose-sorbitol mixture on small intestinal transit in healthy volunteers," *Digestive Diseases and Sciences*, vol. 51, no. 1, pp. 147–153, 2006.
- [29] J. Dyer, I. S. Wood, A. Palejwala, A. Ellis, and S. P. Shirazi-Beechey, "Expression of monosaccharide transporters in intestine of diabetic humans," *American Journal of Physiology: Gastrointestinal and Liver Physiology*, vol. 282, no. 2, pp. G241–G248, 2002.
- [30] G. L. Kellett and E. Brot-Laroche, "Apical GLUT2—a major pathway of intestinal sugar absorption," *Diabetes*, vol. 54, no. 10, pp. 3056–3062, 2005.
- [31] C. M. F. Kneepkens, R. J. Vonk, and J. Fernandes, "Incomplete intestinal absorption of fructose," *Archives of Disease in Childhood*, vol. 59, no. 8, pp. 735–738, 1984.
- [32] V. Douard and R. P. Ferraris, "Regulation of the fructose transporter GLUT5 in health and disease," *American Journal of Physiology—Endocrinology and Metabolism*, vol. 295, no. 2, pp. E227–E237, 2008.
- [33] G. A. Bray, "How bad is fructose?" *The American Journal of Clinical Nutrition*, vol. 86, no. 4, pp. 895–896, 2007.
- [34] O. Bjorkman, M. Crump, and R. W. Phillips, "Intestinal metabolism of orally administered glucose and fructose in Yucatan miniature swine," *The Journal of Nutrition*, vol. 114, no. 8, pp. 1413–1420, 1984.

- [35] O. Bjorkman and P. Felig, "Role of the kidney in the metabolism of fructose in 60-hour fasted humans," *Diabetes*, vol. 31, no. 6, pp. 516–520, 1982.
- [36] G. J. Litherland, E. Hajduch, G. W. Gould, and H. S. Hundal, "Fructose transport and metabolism in adipose tissue of Zucker rats: diminished GLUT5 activity during obesity and insulin resistance," *Molecular and Cellular Biochemistry*, vol. 261, no. 1, pp. 23–33, 2004.
- [37] P. Lam, K. Ng, K. L. Stanhope et al., "Effects of consuming dietary fructose versus glucose on de novo lipogenesis in overweight and obese human subjects," *Berkeley Scientific Journal*, vol. 15, no. 2, 2011.
- [38] L. Tappy and K.-A. Lê, "Does fructose consumption contribute to non-alcoholic fatty liver disease?" *Clinics and Research in Hepatology and Gastroenterology*, vol. 36, no. 6, pp. 554–560, 2012.
- [39] K. L. Stanhope, "Role of fructose-containing sugars in the epidemics of obesity and metabolic syndrome," *Annual Review of Medicine*, vol. 63, pp. 329–343, 2012.
- [40] V. T. Samuel, "Fructose induced lipogenesis: from sugar to fat to insulin resistance," *Trends in Endocrinology and Metabolism*, vol. 22, no. 2, pp. 60–65, 2011.
- [41] P. A. Mayes, "Intermediary metabolism of fructose," *American Journal of Clinical Nutrition*, vol. 58, no. 5, pp. S754–S765, 1993.
- [42] J. Delarue, S. Normand, C. Pachiardi, M. Beylot, F. Lamisse, and J. P. Riou, "The contribution of naturally labelled ^{13}C fructose to glucose appearance in humans," *Diabetologia*, vol. 36, no. 4, pp. 338–345, 1993.
- [43] S. Z. Sun and M. W. Empie, "Fructose metabolism in humans—what isotopic tracer studies tell us," *Nutrition & Metabolism*, vol. 9, article 89, 2012.
- [44] L. H. Smith Jr., R. H. Ettinger, and D. Seligson, "A comparison of the metabolism of fructose and glucose in hepatic," *The Journal of Clinical Investigation*, vol. 32, no. 4, pp. 273–282, 1953.
- [45] H. Sahebhami and R. Scalettar, "Effects of fructose infusion on lactate and uric acid metabolism," *The Lancet*, vol. 297, no. 7695, pp. 366–369, 1971.
- [46] J.-M. Schwarz, Y. Schutz, F. Froidevaux et al., "Thermogenesis in men and women induced by fructose vs glucose added to a meal," *American Journal of Clinical Nutrition*, vol. 49, no. 4, pp. 667–674, 1989.
- [47] C. Couchepin, L. Ê. Kim-Anne, M. Bortolotti et al., "Markedly blunted metabolic effects of fructose in healthy young female subjects compared with male subjects," *Diabetes Care*, vol. 31, no. 6, pp. 1254–1256, 2008.
- [48] V. Lecoultrre, R. Benoit, G. Carrel et al., "Fructose and glucose co-ingestion during prolonged exercise increases lactate and glucose fluxes and oxidation compared with an equimolar intake of glucose," *The American Journal of Clinical Nutrition*, vol. 92, no. 5, pp. 1071–1079, 2010.
- [49] J. L. Kelsay, K. M. Behall, and W. M. Clark, "Glucose, fructose, lactate and pyruvate in blood, and lactate and pyruvate in parotid saliva in response to sugars with and without other foods," *American Journal of Clinical Nutrition*, vol. 27, no. 8, pp. 819–825, 1974.
- [50] F. Theytaz, S. de Giorgi, L. Hodson et al., "Metabolic fate of fructose ingested with and without glucose in a mixed meal," *Nutrients*, vol. 6, no. 7, pp. 2632–2649, 2014.
- [51] K. L. Teff, S. S. Elliott, M. Tschöp et al., "Dietary fructose reduces circulating insulin and leptin, attenuates postprandial suppression of ghrelin, and increases triglycerides in women," *The Journal of Clinical Endocrinology & Metabolism*, vol. 89, no. 6, pp. 2963–2972, 2004.
- [52] J. Girard, "The inhibitory effects of insulin on hepatic glucose production are both direct and indirect," *Diabetes*, vol. 55, no. 2, pp. S65–S69, 2006.
- [53] G. Boden, S. Salehi, P. Cheung et al., "Comparison of in vivo effects of insulin on SREBP-1c activation and INSIG-1/2 in rat liver and human and rat adipose tissue," *Obesity*, vol. 21, no. 6, pp. 1208–1214, 2013.
- [54] M. K. Hellerstein, J.-M. Schwarz, and R. A. Neese, "Regulation of hepatic de novo lipogenesis in humans," *Annual Review of Nutrition*, vol. 16, pp. 523–557, 1996.
- [55] E. Shrago, J. A. Glennon, and E. S. Gordon, "Comparative aspects of lipogenesis in mammalian tissues," *Metabolism: Clinical and Experimental*, vol. 20, no. 1, pp. 54–62, 1971.
- [56] Z. K. Guo, L. K. Cella, C. Baum, E. Ravussin, and D. A. Schoeller, "De novo lipogenesis in adipose tissue of lean and obese women: application of deuterated water and isotope ratio mass spectrometry," *International Journal of Obesity*, vol. 24, no. 7, pp. 932–937, 2000.
- [57] F. Diraison, V. Yankah, D. Letexier, E. Dusserre, P. Jones, and M. Beylot, "Differences in the regulation of adipose tissue and liver lipogenesis by carbohydrates in humans," *Journal of Lipid Research*, vol. 44, no. 4, pp. 846–853, 2003.
- [58] A. Strawford, F. Antelo, M. Christiansen, and M. K. Hellerstein, "Adipose tissue triglyceride turnover, de novo lipogenesis, and cell proliferation in humans measured with $^2\text{H}_2\text{O}$," *American Journal of Physiology—Endocrinology & Metabolism*, vol. 286, no. 4, pp. E577–E588, 2004.
- [59] C. Chascione, D. H. Elwyn, M. Davila, K. M. Gil, J. Askanazi, and J. M. Kinney, "Effect of carbohydrate intake on de novo lipogenesis in human adipose tissue," *American Journal of Physiology: Endocrinology and Metabolism*, vol. 253, no. 6, pp. E664–E669, 1987.
- [60] A. Aarsland, D. Chinkes, and R. R. Wolfe, "Hepatic and whole-body fat synthesis in humans during carbohydrate overfeeding," *The American Journal of Clinical Nutrition*, vol. 65, no. 6, pp. 1774–1782, 1997.
- [61] R. J. Stubbs, N. Mazlan, and S. Whybrow, "Carbohydrates, appetite and feeding behavior in humans," *The Journal of Nutrition*, vol. 131, no. 10, pp. 2775S–2781S, 2001.
- [62] K. J. Acheson, Y. Schutz, T. Bessard, K. Anantharaman, J.-P. Flatt, and E. Jequier, "Glycoprotein storage capacity and de novo lipogenesis during massive carbohydrate overfeeding in man," *American Journal of Clinical Nutrition*, vol. 48, no. 2, pp. 240–247, 1988.
- [63] E. J. Parks, L. E. Skokan, M. T. Timlin, and C. S. Dingfelder, "Dietary sugars stimulate fatty acid synthesis in adults," *Journal of Nutrition*, vol. 138, no. 6, pp. 1039–1046, 2008.
- [64] O.-J. Park, D. Cesar, D. Faix, K. Wu, C. H. L. Shackleton, and M. K. Hellerstein, "Mechanisms of fructose-induced hypertriglyceridaemia in the rat. Activation of hepatic pyruvate dehydrogenase through inhibition of pyruvate dehydrogenase kinase," *Biochemical Journal*, vol. 282, no. 3, pp. 753–757, 1992.
- [65] K. L. Stanhope, J. M. Schwarz, N. L. Keim et al., "Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans," *The Journal of Clinical Investigation*, vol. 119, no. 5, pp. 1322–1334, 2009.
- [66] R. Crescenzo, F. Bianco, I. Falcone, P. Coppola, G. Liverini, and S. Iossa, "Increased hepatic de novo lipogenesis and

- mitochondrial efficiency in a model of obesity induced by diets rich in fructose," *European Journal of Nutrition*, vol. 52, no. 2, pp. 537–545, 2013.
- [67] T. J. Carden and T. P. Carr, "Food availability of glucose and fat, but not fructose, increased in the US between 1970 and 2009: analysis of the USDA food availability data system," *Nutrition Journal*, vol. 12, article 130, 2013.
- [68] K. M. Hirahatake, J. K. Meissen, O. Fiehn, and S. H. Adams, "Comparative effects of fructose and glucose on lipogenic gene expression and intermediary metabolism in HepG2 liver cells," *PLoS ONE*, vol. 6, no. 11, Article ID e26583, 2011.
- [69] J. R. Dushay, E. Toschi, E. K. Mitten, F. M. Fisher, M. A. Herman, and E. Maratos-Flier, "Fructose ingestion acutely stimulates circulating FGF21 levels in humans," *Molecular Metabolism*, vol. 4, no. 1, pp. 51–57, 2014.
- [70] T. Bobbert, F. Schwarz, A. Fischer-Rosinsky et al., "Fibroblast growth factor 21 predicts the metabolic syndrome and type 2 diabetes in Caucasians," *Diabetes Care*, vol. 36, no. 1, pp. 145–149, 2013.
- [71] D. Faeh, K. Minehira, J.-M. Schwarz, R. Periasami, P. Seongsu, and L. Tappy, "Effect of fructose overfeeding and fish oil administration on hepatic de novo lipogenesis and insulin sensitivity in healthy men," *Diabetes*, vol. 54, no. 7, pp. 1907–1913, 2005.
- [72] V. Ha, J. L. Sievenpiper, R. J. De Souza et al., "Effect of fructose on blood pressure: a systematic review and meta-analysis of controlled feeding trials," *Hypertension*, vol. 59, no. 4, pp. 787–795, 2012.
- [73] M. F.-F. Chong, B. A. Fielding, and K. N. Frayn, "Mechanisms for the acute effect of fructose on postprandial lipemia," *The American Journal of Clinical Nutrition*, vol. 85, no. 6, pp. 1511–1520, 2007.
- [74] A. Vedala, W. Wang, R. A. Neese, M. P. Christiansen, and M. K. Hellerstein, "Delayed secretory pathway contributions to VLDL-triglycerides from plasma NEFA, diet, and de novo lipogenesis in humans," *Journal of Lipid Research*, vol. 47, no. 11, pp. 2562–2574, 2006.
- [75] K. L. Stanhope and P. J. Havel, "Fructose consumption: potential mechanisms for its effects to increase visceral adiposity and induce dyslipidemia and insulin resistance," *Current Opinion in Lipidology*, vol. 19, no. 1, pp. 16–24, 2008.
- [76] I. Marques-Lopes, D. Ansorena, I. Astiasaran, L. Forga, and J. A. Martínez, "Postprandial de novo lipogenesis and metabolic changes induced by a high-carbohydrate, low-fat meal in lean and overweight men," *The American Journal of Clinical Nutrition*, vol. 73, no. 2, pp. 253–261, 2001.
- [77] J. D. Horton, J. L. Goldstein, and M. S. Brown, "SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver," *Journal of Clinical Investigation*, vol. 109, no. 9, pp. 1125–1131, 2002.
- [78] C. Tran, D. Jacot-Descombes, V. Lecoultre et al., "Sex differences in lipid and glucose kinetics after ingestion of an acute oral fructose load," *British Journal of Nutrition*, vol. 104, no. 8, pp. 1139–1147, 2010.
- [79] L. C. Hudgins, M. K. Hellerstein, C. E. Seidman, R. A. Neese, J. D. Tremaroli, and J. Hirsch, "Relationship between carbohydrate-induced hypertriglyceridemia and fatty acid synthesis in lean and obese subjects," *Journal of Lipid Research*, vol. 41, no. 4, pp. 595–604, 2000.
- [80] M. T. Timlin and E. J. Parks, "Temporal pattern of de novo lipogenesis in the postprandial state in healthy men," *American Journal of Clinical Nutrition*, vol. 81, no. 1, pp. 35–42, 2005.
- [81] K.-A. Le, M. Ith, R. Kreis et al., "Fructose overconsumption causes dyslipidemia and ectopic lipid deposition in healthy subjects with and without a family history of type 2 diabetes," *The American Journal of Clinical Nutrition*, vol. 89, no. 6, pp. 1760–1765, 2009.
- [82] R. J. L. Allen and J. S. Leahy, "Some effects of dietary dextrose, fructose, liquid glucose and sucrose in the adult male rat," *British Journal of Nutrition*, vol. 20, no. 2, pp. 339–347, 1966.
- [83] I. Bergheim, S. Weber, M. Vos et al., "Antibiotics protect against fructose-induced hepatic lipid accumulation in mice: role of endotoxin," *Journal of Hepatology*, vol. 48, no. 6, pp. 983–992, 2008.
- [84] K.-A. Lê, D. Faeh, R. Stettler et al., "A 4-wk high-fructose diet alters lipid metabolism without affecting insulin sensitivity or ectopic lipids in healthy humans," *American Journal of Clinical Nutrition*, vol. 84, no. 6, pp. 1374–1379, 2006.
- [85] G. Silbernagel, J. MacHann, S. Unmuth et al., "Effects of 4-week very-high-fructose/glucose diets on insulin sensitivity, visceral fat and intrahepatic lipids: an exploratory trial," *British Journal of Nutrition*, vol. 106, no. 1, pp. 79–86, 2011.
- [86] J. L. Sievenpiper, R. J. de Souza, A. I. Cozma, L. Chiavaroli, V. Ha, and A. Mirrahimi, "Fructose vs. glucose and metabolism: do the metabolic differences matter?" *Current Opinion in Lipidology*, vol. 25, no. 1, pp. 8–19, 2014.
- [87] S. Chiu, J. L. Sievenpiper, R. J. de Souza et al., "Effect of fructose on markers of non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of controlled feeding trials," *European Journal of Clinical Nutrition*, vol. 68, no. 4, pp. 416–423, 2014.
- [88] S. Bravo, J. Lowndes, S. Sinnett, Z. Yu, and J. Rippe, "Consumption of sucrose and high-fructose corn syrup does not increase liver fat or ectopic fat deposition in muscles," *Applied Physiology, Nutrition and Metabolism*, vol. 38, no. 6, pp. 681–688, 2013.
- [89] J. M. Rippe and T. J. Angelopoulos, "Sucrose, high-fructose corn syrup, and fructose, their metabolism and potential health effects: what do we really know?" *Advances in Nutrition*, vol. 4, no. 2, pp. 236–245, 2013.
- [90] M. Maersk, A. Belza, H. Stødkilde-Jørgensen et al., "Sucrose-sweetened beverages increase fat storage in the liver, muscle, and visceral fat depot: a 6-mo randomized intervention study," *The American Journal of Clinical Nutrition*, vol. 95, no. 2, pp. 283–289, 2012.
- [91] R. D. Johnston, M. C. Stephenson, H. Crossland et al., "No difference between high-fructose and high-glucose diets on liver triacylglycerol or biochemistry in healthy overweight men," *Gastroenterology*, vol. 145, no. 5, pp. 1016–1025, 2013.
- [92] K. A. Page, O. Chan, J. Arora et al., "Effects of fructose vs glucose on regional cerebral blood flow in brain regions involved with appetite and reward pathways," *The Journal of the American Medical Association*, vol. 309, no. 1, pp. 63–70, 2013.
- [93] J. B. Moore, P. J. Gunn, and B. A. Fielding, "The role of dietary sugars and de novo lipogenesis in non-alcoholic fatty liver disease," *Nutrients*, vol. 6, no. 12, pp. 5679–5703, 2014.
- [94] S. W. Rizkalla, "Health implications of fructose consumption: a review of recent data," *Nutrition & Metabolism*, vol. 7, article 82, 2010.
- [95] A. Aarsland and R. R. Wolfe, "Hepatic secretion of VLDL fatty acids during stimulated lipogenesis in men," *Journal of Lipid Research*, vol. 39, no. 6, pp. 1280–1286, 1998.
- [96] W. E. Connor, "Harbingers of coronary heart disease: dietary saturated fatty acids and cholesterol. Is chocolate benign

- because of its stearic acid content?" *The American Journal of Clinical Nutrition*, vol. 70, no. 6, pp. 951–952, 1999.
- [97] J. C. Cohen and R. Schall, "Reassessing the effects of simple carbohydrates on the serum triglyceride responses to fat meals," *American Journal of Clinical Nutrition*, vol. 48, no. 4, pp. 1031–1034, 1988.
- [98] K. L. Teff, J. Grudziak, R. R. Townsend et al., "Endocrine and metabolic effects of consuming fructose- and glucose-sweetened beverages with meals in obese men and women: influence of insulin resistance on plasma triglyceride responses," *The Journal of Clinical Endocrinology & Metabolism*, vol. 94, no. 5, pp. 1562–1569, 2009.
- [99] J. Hallfrisch, S. Reiser, and E. S. Prather, "Blood lipid distribution of hyperinsulinemic men consuming three levels of fructose," *The American Journal of Clinical Nutrition*, vol. 37, no. 5, pp. 740–748, 1983.
- [100] S. Reiser, A. S. Powell, D. J. Scholfield, P. Panda, K. C. Ellwood, and J. J. Canary, "Blood lipids, lipoproteins, apoproteins, and uric acid in men fed diets containing fructose or high-amylose cornstarch," *The American Journal of Clinical Nutrition*, vol. 49, no. 5, pp. 832–839, 1989.
- [101] J. P. Bantle, J. E. Swanson, W. Thomas, and D. C. Laine, "Metabolic effects of dietary fructose in diabetic subjects," *Diabetes Care*, vol. 15, no. 11, pp. 1468–1476, 1992.
- [102] J. E. Swanson, D. C. Laine, W. Thomas, and J. P. Bantle, "Metabolic effects of dietary fructose in healthy subjects," *American Journal of Clinical Nutrition*, vol. 55, no. 4, pp. 851–856, 1992.
- [103] K. L. Stanhope, A. A. Bremer, V. Medici et al., "Consumption of fructose and high fructose corn syrup increase postprandial triglycerides, LDL-cholesterol, and apolipoprotein-B in young men and women," *Journal of Clinical Endocrinology and Metabolism*, vol. 96, no. 10, pp. E1596–E1605, 2011.
- [104] I. Aeberli, P. A. Gerber, M. Hochuli et al., "Low to moderate sugar-sweetened beverage consumption impairs glucose and lipid metabolism and promotes inflammation in healthy young men: a randomized controlled trial," *The American Journal of Clinical Nutrition*, vol. 94, no. 2, pp. 479–485, 2011.
- [105] M. R. Diffenderfer and E. J. Schaefer, "The composition and metabolism of large and small LDL," *Current Opinion in Lipidology*, vol. 25, no. 3, pp. 221–226, 2014.
- [106] G. Livesey and R. Taylor, "Fructose consumption and consequences for glycation, plasma triacylglycerol, and body weight: meta-analyses and meta-regression models of intervention studies," *The American Journal of Clinical Nutrition*, vol. 88, no. 5, pp. 1419–1437, 2008.
- [107] M. M. Swarbrick, K. L. Stanhope, S. S. Elliott et al., "Consumption of fructose-sweetened beverages for 10 weeks increases postprandial triacylglycerol and apolipoprotein-B concentrations in overweight and obese women," *British Journal of Nutrition*, vol. 100, no. 5, pp. 947–952, 2008.
- [108] D. David Wang, J. L. Sievenpiper, R. J. De Souza et al., "Effect of fructose on postprandial triglycerides: a systematic review and meta-analysis of controlled feeding trials," *Atherosclerosis*, vol. 232, no. 1, pp. 125–133, 2014.
- [109] I. Aeberli, M. Hochuli, P. A. Gerber et al., "Moderate amounts of fructose consumption impair insulin sensitivity in healthy young men: a randomized controlled trial," *Diabetes Care*, vol. 36, no. 1, pp. 150–156, 2013.
- [110] J. Lowndes, S. Sinnett, S. Pardo et al., "The effect of normally consumed amounts of sucrose or high fructose corn syrup on lipid profiles, body composition and related parameters in overweight/obese subjects," *Nutrients*, vol. 6, no. 3, pp. 1128–1144, 2014.
- [111] J. M. Rippe, "The metabolic and endocrine response and health implications of consuming sugar-sweetened beverages: findings from recent randomized controlled trials," *Advances in Nutrition*, vol. 4, no. 6, pp. 677–686, 2013.
- [112] M. Hashemi, M. Yavari, N. Amiri et al., "Uric acid: a risk factor for coronary atherosclerosis?" *Cardiovascular Journal of South Africa*, vol. 18, no. 1, pp. 16–19, 2007.
- [113] T. C. Rodrigues, D. M. Maahs, R. J. Johnson et al., "Serum uric acid predicts progression of subclinical coronary atherosclerosis in individuals without renal disease," *Diabetes Care*, vol. 33, no. 11, pp. 2471–2473, 2010.
- [114] D. I. Feig, D.-H. Kang, and R. J. Johnson, "Uric acid and cardiovascular risk," *The New England Journal of Medicine*, vol. 359, no. 17, pp. 1811–1821, 2008.
- [115] C. L. Cox, K. L. Stanhope, J. M. Schwarz et al., "Consumption of fructose- but not glucose-sweetened beverages for 10 weeks increases circulating concentrations of uric acid, retinol binding protein-4, and gamma-glutamyl transferase activity in overweight/obese humans," *Nutrition & Metabolism*, vol. 9, article 68, 2012.
- [116] D. D. Wang, J. L. Sievenpiper, R. J. de Souza et al., "The effects of fructose intake on serum uric acid vary among controlled dietary trials," *The Journal of Nutrition*, vol. 142, no. 5, pp. 916–923, 2012.
- [117] J. Perheentupa and K. Raivio, "Fructose-induced hyperuricaemia," *The Lancet*, vol. 2, no. 7515, pp. 528–531, 1967.
- [118] C. M. Brown, A. G. Dulloo, G. Yepuri, and J.-P. Montani, "Fructose ingestion acutely elevates blood pressure in healthy young humans," *The American Journal of Physiology—Regulatory Integrative and Comparative Physiology*, vol. 294, no. 3, pp. R730–R737, 2008.
- [119] S. E. Perez-Pozo, J. Schold, T. Nakagawa, L. G. Sánchez-Lozada, R. J. Johnson, and J. L. Lillo, "Excessive fructose intake induces the features of metabolic syndrome in healthy adult men: role of uric acid in the hypertensive response," *International Journal of Obesity*, vol. 34, no. 3, pp. 454–461, 2010.
- [120] V. H. Jayalath, J. L. Sievenpiper, R. J. de Souza et al., "Total fructose intake and risk of hypertension: a systematic review and meta-analysis of prospective cohorts," *Journal of the American College of Nutrition*, vol. 33, no. 4, pp. 328–339, 2014.
- [121] V. Ha, V. H. Jayalath, A. I. Cozma, A. Mirrahimi, R. J. de Souza, and J. L. Sievenpiper, "Fructose-containing sugars, blood pressure, and cardiometabolic risk: a critical review," *Current Hypertension Reports*, vol. 15, no. 4, pp. 281–297, 2013.
- [122] M. Wang, M. Yu, L. Fang, and R. Hu, "Association between sugar-sweetened beverages and type 2 diabetes: a meta-analysis," *Journal of Diabetes Investigation*, vol. 6, no. 3, pp. 360–366, 2015.
- [123] M.-F. Kong, I. Chapman, E. Goble et al., "Effects of oral fructose and glucose on plasma GLP-1 and appetite in normal subjects," *Peptides*, vol. 20, no. 5, pp. 545–551, 1999.
- [124] A. M. Grant, M. R. Christie, and S. J. H. Ashcroft, "Insulin release from human pancreatic islets in vitro," *Diabetologia*, vol. 19, no. 2, pp. 114–117, 1980.
- [125] D. L. Curry, "Effects of mannose and fructose on the synthesis and secretion of insulin," *Pancreas*, vol. 4, no. 1, pp. 2–9, 1989.
- [126] A. I. Cozma, J. L. Sievenpiper, R. J. de Souza et al., "Effect of fructose on glycemic control in diabetes: a systematic review

- and meta-analysis of controlled feeding trials," *Diabetes Care*, vol. 35, no. 7, pp. 1611–1620, 2012.
- [127] J. L. Sievenpiper, L. Chiavaroli, R. J. De Souza et al., "Catalytic doses of fructose may benefit glycaemic control without harming cardiometabolic risk factors: A small meta-analysis of randomised controlled feeding trials," *British Journal of Nutrition*, vol. 108, no. 3, pp. 418–423, 2012.
- [128] I. S. Hwang, H. Ho, B. B. Hoffman, and G. M. Reaven, "Fructose-induced insulin resistance and hypertension in rats," *Hypertension*, vol. 10, no. 5, pp. 512–516, 1987.
- [129] Y.-J. Huang, V. S. Fang, C.-C. Juan, Y.-C. Chou, C.-F. Kwok, and L.-T. Ho, "Amelioration of insulin resistance and hypertension in a fructose-fed rat model with fish oil supplementation," *Metabolism: Clinical and Experimental*, vol. 46, no. 11, pp. 1252–1258, 1997.
- [130] P. A. Crapo and O. G. Kolterman, "The metabolic effects of 2-week fructose feeding in normal subjects," *The American Journal of Clinical Nutrition*, vol. 39, no. 4, pp. 525–534, 1984.
- [131] G. Grigoresco, S. W. Rizkalla, P. Halfon et al., "Lack of detectable deleterious effects on metabolic control of daily fructose ingestion for 2-mo in NIDDM patients," *Diabetes Care*, vol. 11, no. 7, pp. 546–550, 1988.
- [132] A. L. Sunehag, G. Toffolo, M. S. Treuth et al., "Effects of dietary macronutrient content on glucose metabolism in children," *Journal of Clinical Endocrinology & Metabolism*, vol. 87, no. 11, pp. 5168–5178, 2002.
- [133] R. D. Feinman and E. J. Fine, "Fructose in perspective," *Nutrition & Metabolism*, vol. 10, no. 1, article 45, 2013.
- [134] H. Beck-Nielsen, O. Pedersen, and H. O. Lindskov, "Impaired cellular insulin binding and insulin sensitivity induced by high-fructose feeding in normal subjects," *The American Journal of Clinical Nutrition*, vol. 33, no. 2, pp. 273–278, 1980.
- [135] J. Hallfrisch, K. C. Ellwood, O. E. Michaelis, S. Reiser, T. M. O'Dorisio, and E. S. Prather, "Effects of dietary fructose on plasma-glucose and hormone responses in normal and hyperinsulinemic men," *The Journal of Nutrition*, vol. 113, no. 9, pp. 1819–1826, 1983.
- [136] K. C. Eiffert, R. B. McDonald, and J. S. Stern, "High sucrose diet and exercise: effects on insulin-receptor function of 12- and 24-mo-old Sprague-Dawley rats," *Journal of Nutrition*, vol. 121, no. 7, pp. 1081–1089, 1991.
- [137] Y. Wei and M. J. Pagliassotti, "Hepatospecific effects of fructose on c-jun NH2-terminal kinase: implications for hepatic insulin resistance," *American Journal of Physiology—Endocrinology and Metabolism*, vol. 287, no. 5, pp. E926–E933, 2004.
- [138] Y. Nagai, S. Yonemitsu, D. M. Erion et al., "The role of peroxisome proliferator-activated receptor gamma coactivator-1 β in the pathogenesis of fructose-induced insulin resistance," *Cell Metabolism*, vol. 9, no. 3, pp. 252–264, 2009.
- [139] S. Delbosc, E. Paizanis, R. Magous et al., "Involvement of oxidative stress and NADPH oxidase activation in the development of cardiovascular complications in a model of insulin resistance, the fructose-fed rat," *Atherosclerosis*, vol. 179, no. 1, pp. 43–49, 2005.
- [140] K. L. Stanhope, S. C. Griffen, B. R. Bair, M. M. Swarbrick, N. L. Keim, and P. J. Havel, "Twenty-four-hour endocrine and metabolic profiles following consumption of high-fructose corn syrup-, sucrose-, fructose-, and glucose-sweetened beverages with meals," *The American Journal of Clinical Nutrition*, vol. 87, no. 5, pp. 1194–1203, 2008.
- [141] L. T. Tran, V. G. Yuen, and J. H. McNeill, "The fructose-fed rat: a review on the mechanisms of fructose-induced insulin resistance and hypertension," *Molecular and Cellular Biochemistry*, vol. 332, no. 1-2, pp. 145–159, 2009.
- [142] J. Rodin, D. Reed, and L. Jamner, "Metabolic effects of fructose and glucose: implications for food intake," *American Journal of Clinical Nutrition*, vol. 47, no. 4, pp. 683–689, 1988.
- [143] J. Rodin, "Comparative effects of fructose, aspartame, glucose, and water preloads on calorie and macronutrient intake," *The American Journal of Clinical Nutrition*, vol. 51, no. 3, pp. 428–435, 1990.
- [144] L. Spitzer and J. Rodin, "Effects of fructose and glucose preloads on subsequent food-intake," *Appetite*, vol. 8, no. 2, pp. 135–145, 1987.
- [145] Z. S. Warwick and H. P. Weingarten, "Dynamics of intake suppression after a preload: role of calories, volume, and macronutrients," *The American Journal of Physiology—Regulatory Integrative and Comparative Physiology*, vol. 266, no. 4, pp. R1314–R1318, 1994.
- [146] L. Tappy, J.-P. Randin, J.-P. Felber et al., "Comparison of thermogenic effect of fructose and glucose in normal humans," *The American Journal of Physiology—Endocrinology and Metabolism*, vol. 250, no. 6, pp. E718–E724, 1986.
- [147] D. C. Simonson, L. Tappy, E. Jequier, J.-P. Felber, and R. A. DeFronzo, "Normalization of carbohydrate-induced thermogenesis by fructose in insulin-resistant states," *The American Journal of Physiology—Endocrinology and Metabolism*, vol. 254, no. 2, pp. E201–E207, 1988.
- [148] J.-M. Schwarz, K. J. Acheson, L. Tappy et al., "Thermogenesis and fructose metabolism in humans," *American Journal of Physiology: Endocrinology and Metabolism*, vol. 262, no. 5, pp. E591–E598, 1992.
- [149] J. Hugenholtz, "The lactic acid bacterium as a cell factory for food ingredient production," *International Dairy Journal*, vol. 18, no. 5, pp. 466–475, 2008.
- [150] M.-J. Gwak, S.-J. Chung, Y. J. Kim, and C. S. Lim, "Relative sweetness and sensory characteristics of bulk and intense sweeteners," *Food Science and Biotechnology*, vol. 21, no. 3, pp. 889–894, 2012.
- [151] R. S. Shallenberger, "Intrinsic chemistry of fructose," *Pure and Applied Chemistry*, vol. 50, no. 11-12, pp. 1409–1420, 1978.
- [152] R. E. Wrolstad, *Food Carbohydrate Chemistry*, John Wiley & Sons, New York, NY, USA, 1st edition, 2012.
- [153] S. R. Blakely, J. Hallfrisch, S. Reiser, and E. S. Prather, "Long-term effects of moderate fructose feeding on glucose-tolerance parameters in rats," *The Journal of Nutrition*, vol. 111, no. 2, pp. 307–314, 1981.
- [154] K. L. Stanhope and P. J. Havel, "Endocrine and metabolic effects of consuming beverages sweetened with fructose, glucose, sucrose, or high-fructose corn syrup," *The American Journal of Clinical Nutrition*, vol. 88, no. 6, pp. 1733S–1737S, 2008.
- [155] J. L. Sievenpiper, R. J. de Souza, A. Mirrahimi et al., "Effect of fructose on body weight in controlled feeding trials: a systematic review and meta-analysis," *Annals of Internal Medicine*, vol. 156, no. 4, pp. 291–304, 2012.
- [156] J.-M. Schwarz, P. Linfoot, D. Dare, and K. Aghajanian, "Hepatic de novo lipogenesis in normoinsulinemic and hyperinsulinemic subjects consuming high-fat, low-carbohydrate and low-fat, high-carbohydrate isoenergetic diets," *The American Journal of Clinical Nutrition*, vol. 77, no. 1, pp. 43–50, 2003.
- [157] K. N. Frayn, P. Lund, and M. Walker, "Interpretation of oxygen and carbon dioxide exchange across tissue beds in vivo," *Clinical Science*, vol. 85, no. 4, pp. 373–384, 1993.

- [158] E. E. Blaak and W. H. M. Saris, "Postprandial thermogenesis and substrate utilization after ingestion of different dietary carbohydrates," *Metabolism: Clinical and Experimental*, vol. 45, no. 10, pp. 1235–1242, 1996.
- [159] E. Ferrannini, "The theoretical bases of indirect calorimetry: a review," *Metabolism: Clinical and Experimental*, vol. 37, no. 3, pp. 287–301, 1988.
- [160] L. Tappy and B. Mittendorfer, "Fructose toxicity: is the science ready for public health actions?" *Current Opinion in Clinical Nutrition and Metabolic Care*, vol. 15, no. 4, pp. 357–361, 2012.
- [161] M. B. Vos, J. E. Kimmons, C. Gillespie, J. Welsh, and H. M. Blank, "Dietary fructose consumption among US children and adults: the Third National Health and Nutrition Examination Survey," *The Medscape Journal of Medicine*, vol. 10, no. 7, article 160, 2008.
- [162] M. Sland, M. Haugen, F.-L. Eriksen et al., "High sugar consumption and poor nutrient intake among drug addicts in Oslo, Norway," *British Journal of Nutrition*, vol. 105, no. 4, pp. 618–624, 2011.



Hindawi
Submit your manuscripts at
<http://www.hindawi.com>

